Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was $0, compared with $903 a year earlier. Trailing-twelve-month depreciation & amortization was $876. Over 3 fiscal years it compounded at -21.0% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $219.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.78K USD
- Year-over-year change
- -50.7%
- 4-year CAGR
- -16.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.78K | -50.7% |
| FY2024 | 2024-12-31 | 3.61K | +0.0% |
| FY2023 | 2023-12-31 | 3.61K | +0.0% |
| FY2022 | 2022-12-31 | 3.61K | +0.0% |
| FY2021 | 2021-12-31 | 3.61K | — |
Depreciation & Amortization vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -75.7% is the 7th highest of 9, against a peer median of -2.4%.
- Over three fiscal years its annual growth of -21.0% compares with a peer median of +3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.38M USD | -44.0% | +12.9% | 6.0% | |
| LTM Mar 2026 | $6.03M USD | -3.9% | +1.1% | 40.1% | |
| LTM Mar 2026 | $398.22K USD | +164.2% | +454.8% | — | |
| LTM Mar 2026 | $308K USD | -77.1% | -35.0% | 4.1% | |
| LTM Mar 2026 | $251K USD | -0.8% | -1.0% | — | |
| LTM Mar 2026 | $80.68K USD | +3.8% | +5.9% | — | |
| LTM Mar 2026 | CA$75.25K CAD | -79.8% | -31.7% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K USD | +241.9% | +136.6% | 0.4% |
| LTM Mar 2026 | $876 USD | -75.7% | -21.0% | — | |
| Peer median (excluding GLSI) | — | -2.4% | +3.5% | 5.0% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Gross Profit | (3.61K) | (3.61K) | (3.61K) | (3.61K) | (1.78K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.56M | 6.48M | 7.7M | 15.48M | 17.22M |
| Selling, General & Admin | 1.04M | 1.56M | 1.63M | 2.15M | 2.23M |
| Operating Expenses | 4.59M | 8.04M | 9.32M | 17.63M | 19.45M |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| EBITDA | (4.57M) | (7.82M) | (8.89M) | (17.41M) | (19.36M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.6M) | (8.04M) | (9.33M) | (17.64M) | (19.45M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Income Before Tax | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| EPS (Diluted) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| Weighted Avg Shares | 12.94M | 12.91M | 12.85M | 13.01M | 13.53M |
| Weighted Avg Shares (Diluted) | 12.94M | 12.91M | 12.85M | 13.01M | 13.53M |
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.